FDA review of Glaxo/Theravance lung drug seen as positive

[riky]

FDA review of Glaxo/Theravance lung drug seen as positive

<p><a href="http://news.yahoo.com/fda-reviewers-data-glaxos-breo-not-consistent-124021026--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/cxlR3CW7AeVKXpunrBl8uw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-04-15T124021Z_1_CBRE93E0Z7D00_RTROPTP_2_BRITAIN.JPG" width="130" height="86" alt="Signage is pictured on the company headquarters of GlaxoSmithKline in west London" align="left" title="Signage is pictured on the company headquarters of GlaxoSmithKline in west London" border="0" /></a>By Toni Clarke WASHINGTON (Reuters) - An experimental treatment for smoking-related lung damage received a better-than-expected initial review from the U.S. Food and Drug Administration, potentially paving the way for a recommendation in favor of approval when an outside panel of experts meets to review the drug later this week. The drug, Breo, is an inhaled treatment for chronic obstructive pulmonary disease (COPD), a condition that includes emphysema, chronic bronchitis or both. COPD is the third leading cause of death in the United States, according to federal data. ...</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login